Cancer Treatment Using Thyroid Hormone Analogs T2 and RT3
Summary
USPTO published patent application US20260097100A1 filed by Keith Roger Latham and Regina L. Garland on September 25, 2025, covering methods and compositions for treating cancer through induction of tumor cell differentiation using thyroid hormone analogs such as T2 and RT3. The application discloses pharmaceutical compositions including topical formulations for skin cancer and delivery systems for systemic administration.
What changed
USPTO published patent application US20260097100A1 disclosing a method and composition for treating cancer through induction of tumor cell differentiation using thyroid hormone analogs including T2 and RT3. The approach converts cancer cells into terminally differentiated, non-proliferating cell types while avoiding cytotoxic effects of conventional chemotherapy. Pharmaceutical compositions include topical formulations for skin cancer and systemic delivery systems. In vitro screening methods for identifying differentiation-inducing agents are also provided.
Affected parties including pharmaceutical researchers, cancer treatment developers, and drug manufacturers should monitor this application for potential licensing opportunities or freedom-to-operate considerations. Patent applications do not grant enforceable rights; inventors must complete examination and meet all requirements to receive an issued patent with enforceable claims.
What to do next
- Monitor for updates on patent examination status
Archived snapshot
Apr 12, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CANCER TREATMENT BY INDUCTION OF TUMOR AND STEM CELL DIFFERENTIATION
Application US20260097100A1 Kind: A1 Apr 09, 2026
Inventors
Keith Roger Latham, Regina L. Garland
Abstract
A method and composition for treating cancer through induction of tumor cell differentiation is disclosed. Cancer cells are converted into terminally differentiated, non-proliferating cell types using specific differentiation-inducing agents, including thyroid hormone analogs such as T2 and RT3. The approach avoids the cytotoxic effects and side effects associated with conventional chemotherapy while potentially providing curative treatment. Pharmaceutical compositions include topical formulations for skin cancer treatment and various delivery systems for systemic administration. In vitro screening methods for identifying differentiation-inducing agents are also provided.
CPC Classifications
A61K 38/22 A61K 9/0014 A61K 47/20 A61P 35/00
Filing Date
2025-09-25
Application No.
19340296
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.